GRAIL (GRAL) Stock Price, News & Analysis

Company Overview

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

Key Stats

• Today's Range: $44.44 to $49.58
• 50-Day Range: $24.85 to $48.44
• 52-Week Range: $12.33 to $63.99
• Volume: 2.22 million shs
• Average Volume: 1.27 million shs
• Market Capitalization: $1.64 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $31.50
• Consensus Rating: Hold

GRAIL Stock Analysis - MarketRank™

GRAIL scored higher than 14% of companies evaluated by MarketBeat, and ranked 868th out of 926 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.1 / 5
• Analyst Rating: Hold

Consensus Rating

GRAIL has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

GRAIL has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for GRAIL are expected to grow in the coming year, from ($15.15) to ($12.95) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of GRAIL is -0.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of GRAIL is -0.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

GRAIL has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

19.93% of the float of GRAIL has been sold short.

Short Interest Ratio / Days to Cover

GRAIL has a short interest ratio ("days to cover") of 4.2.

Change versus previous month

Short interest in GRAIL has recently decreased by 4.52%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

GRAIL does not currently pay a dividend.

Dividend Growth

GRAIL does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

19.93% of the float of GRAIL has been sold short.

Short Interest Ratio / Days to Cover

GRAIL has a short interest ratio ("days to cover") of 4.2.

Change versus previous month

Short interest in GRAIL has recently decreased by 4.52%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.64

News Sentiment

GRAIL has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for GRAIL this week, compared to 7 articles on an average week.

Search Interest

Only 9 people have searched for GRAL on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.

MarketBeat Follows

Only 5 people have added GRAIL to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, GRAIL insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,222,694.00 in company stock.

Percentage Held by Insiders

Only 1.85% of the stock of GRAIL is held by insiders.

GRAL Stock Analysis - Frequently Asked Questions

How have GRAL shares performed this year?

GRAIL's stock was trading at $17.85 at the beginning of the year. Since then, GRAL shares have increased by 155.6% and is now trading at $45.63.
View the best growth stocks for 2025 here.

How were GRAIL's earnings last quarter?

GRAIL, Inc. (NASDAQ:GRAL) announced its quarterly earnings results on Tuesday, May, 13th. The company reported ($3.10) EPS for the quarter, topping the consensus estimate of ($4.03) by $0.93. The company earned $31.84 million during the quarter, compared to the consensus estimate of $35.80 million. GRAIL had a negative trailing twelve-month return on equity of 17.99% and a negative net margin of 1,464.53%.
Read the conference call transcript.

Who are GRAIL's major shareholders?

GRAIL's top institutional investors include Primecap Management Co. CA (5.81%), Sessa Capital IM L.P. (5.43%), Vanguard Group Inc. (4.25%) and AQR Capital Management LLC (3.79%). Insiders that own company stock include Chun R Ding, Robert P Ragusa, Joshua J Ofman and Aaron Freidin.
View institutional ownership trends.

How do I buy shares of GRAIL?

Shares of GRAL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of GRAIL own?

Based on aggregate information from My MarketBeat watchlists, some other companies that GRAIL investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Visa (V).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 6/21/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:GRAL
• Previous Symbol: NASDAQ:GRAL
• CIK: 1699031
• Web: N/A
• Phone: (650) 771-9796
• Fax: N/A
• Employees: 1,360
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $31.50
• High Stock Price Target: $43.00
• Low Stock Price Target: $20.00
• Potential Upside/Downside: -31.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($60.99)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$2.03 billion
• Net Margins: -1,464.53%
• Pretax Margin: -1,594.58%
• Return on Equity: -17.99%
• Return on Assets: -15.02%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.70
• Quick Ratio: 9.71

Sales & Book Value

• Annual Sales: $125.60 million
• Price / Sales: 13.07
• Cash Flow: $27.16 per share
• Price / Cash Flow: 1.68
• Book Value: $74.50 per share
• Price / Book: 0.61

Miscellaneous

• Outstanding Shares: 35,970,000
• Free Float: 35,307,000
• Market Cap: $1.64 billion
• Optionable: Optionable
• Beta: N/A